

## company statement

### Novo Nordisk voluntarily recalls four lots of Wegovy® from pharmacies in the United States

- Voluntary recall initiated out of an abundance of caution; any potential medical risk is considered unlikely or minor
- No action from patients is needed or recommended at this time

**Plainsboro, NJ, December 19, 2025** – Novo Nordisk has chosen to voluntarily issue a retail-level recall of two lots of Wegovy® 0.5 mg (RZFHD52 and RZFW93) and two lots of Wegovy® 1 mg (RZFYK06 and RZFYA53) in the US due to an issue identified in two Wegovy® pen injectors. Both of those pen injectors were caught during inspection and were never sent out to the retail level or patients. There are no confirmed reports of this issue in any Wegovy® pens that are already on the market and no adverse effects known to be related to this issue have been reported from product in these lots to date. No action from patients is needed or recommended at this time and any potential medical risk would most likely be minor.

There is ample supply of Wegovy® in the US market, and no supply disruptions are expected because of this voluntary recall.

Product Description	NDC	Lot Number	Expiration Date	Distribution Dates
Wegovy® 0.5mg	0169-4505-14	RZFHD52	10/31/2026	5/5/2025 - 8/14/2025
		RZFW93	10/31/2026	5/14/2025 - 7/16/2025
Wegovy® 1mg	0169-4501-14	RZFYK06	3/31/2027	10/6/2025 - 11/26/2025
		RZFYA53	3/31/2027	12/1/2025 - 12/2/2025

Patient safety is our top priority, and we are committed to ensuring that all of our products are of the highest quality. We will work closely with the FDA and other stakeholders to ensure an appropriate process is in place related to these four batches so that the recall is handled safely and promptly.

If a patient experiences an adverse reaction to Wegovy®, they should contact their healthcare professional for guidance. Healthcare professionals and customers should report any adverse events or concerns to Novo Nordisk Customer Service at 1-800-727-6500.

### **About Novo Nordisk**

Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 78,500 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs over 10,000 people across more than 10 manufacturing, R&D and corporate locations in eight states plus Washington, D.C. For more information, visit [novonordisk.com](https://novonordisk.com) and [novonordisk-us.com](https://novonordisk-us.com), and follow us on [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

### **Contacts for further information**

#### **Media:**

Liz Skrbkova (US)

+1 609 917 0632

[USmediarelations@novonordisk.com](mailto:USmediarelations@novonordisk.com)

Ambre James-Brown (Global)

+45 3079 9289

[Globalmedia@novonordisk.com](mailto:Globalmedia@novonordisk.com)

#### **Investors:**

Frederik Taylor Pitter (US)

+1 609 613 0568

[fpitr@novonordisk.com](mailto:fpitr@novonordisk.com)

Jacob Martin Wiborg Rode (Global)

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

Sina Meyer (Global)

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)

Max Ung (Global)

+45 3077 6414

[mxun@novonordisk.com](mailto:mxun@novonordisk.com)